It is also noteworthy that long-term follow-up of the patient, particularly during the COVID-19 vaccination period, showed no recurrence of anti-PF4 antibodies after administration of a dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine. The gene discussed is PF4; the disease is COVID-19.